Avanafil is a highly selective PDE5 inhibitor distinguished by rapid onset of action, used for the treatment of erectile dysfunction. Simson Pharma's Avanafil reference standard and impurities support stability-indicating assay development for this fast-acting PDE5-inhibitor therapy.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Avanafil Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.